AC220-168_Quantum Wild https://www.nct-dresden.de/en/trials/910-000000077 https://www.nct-dresden.de/@@site-logo/logo-nct.svg AC220-168_Quantum Wild Category Hematological neoplasms Subcategory Acute myeloid leukemia Trial Type First-Line-Therapy (Metastatic Disease/Hematology) Tumormarkers Description for experts Quizartinib/placebo in combination with induction and consolidation chemotherapy and as maintenance therapy in newly diagnosed FLT3-ITD-negative AML Description for laymen Quizartinib/placebo in combination with induction and consolidation chemotherapy and as maintenance therapy in newly diagnosed FLT3-ITD-negative AML
